Akhil Nair
Research Subjects
Akhil Nair has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Pavithra Pradeep Prabhu
Department of Pharmacognosy, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India
2 shared publications - A. Muthu Bharathi
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmacology, Mangalore, India
1 shared publication - Akhilesh Dubey
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutics, Mangalore, India
1 shared publication - Anvitha Shettigar
Department of Pharmacognosy, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India
1 shared publication - Chakrakodi Shasidhara Shastry
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmacology, Mangalore, India
1 shared publication - Neenu M.K
Department of Pharmacognosy, Yenapoya Pharmacy College & Research Centre, Mangalore, India
1 shared publication
Latest Publications
- Open Access
- 13 July 2026
- Published by Springer Nature in Beni-Suef University Journal of Basic and Applied Sciences
- Vol. 15 (1) , 75
Integrative strategies in herbal product-based Drug discovery: from computational models to molecular insights
Background: Conventional drug discovery process is associated with high costs, lengthy development timelines, and high failure rates mainly for complex multifactorial diseases. These challenges highlight the existing need for various innovative discovery strategies. Natural product continues to play an important role in discovery of drugs, with natural compounds and their derivatives accounting for approximately one-third of all small-molecule drugs that were approved from 1981 to 2019. Main Body: Currently, computational and systems-based approaches are being increasingly incorporated in various steps of herbal-drug discovery. These approaches include molecular docking, virtual screening, quantitative structure-activity relationship (QSAR) modelling, network pharmacology, and bioactivity prediction using machine learning. Other emerging technologies such as genome editing and synthetic biology also provide additional opportunities to access and optimize valuable natural-product metabolites. Together, these tools can aid in identifying candidate molecules, elucidate potential mechanisms, and formulation development, although all of it requires experimental validation. Herbal medicines can modulate multiple molecular targets, hence can be advantageous for complex diseases. Analytical techniques such as hyphenated spectroscopy and metabolomics can further contribute to standardization and quality control. Nanocarrier systems and pharmacogenomic approaches can increase bioavailability and support more personalized therapeutic strategies. This review highlights integrated approaches for improving discovery, validation, and herbal therapeutic development. Conclusion: The combination of traditional knowledge with computational and analytical approaches provides a practical framework for herbal product-based drug discovery. Continued progress will depend on standardization, reproducible methodologies, and robust clinical evidence.
- 13 July 2026
- Published by Springer Nature in Beni-Suef University Journal of Basic and Applied Sciences
- Vol. 15 (1) , 75
Open AccessIntegrative strategies in herbal product-based Drug discovery: from computational models to molecular insights
Background: Conventional drug discovery process is associated with high costs, lengthy development timelines, and high failure rates mainly for complex multifactorial diseases. These challenges highlight the existing need for various innovative discovery strategies. Natural product continues to play an important role in discovery of drugs, with natural compounds and their derivatives accounting for approximately one-third of all small-molecule drugs that were approved from 1981 to 2019. Main Body: Currently, computational and systems-based approaches are being increasingly incorporated in various steps of herbal-drug discovery. These approaches include molecular docking, virtual screening, quantitative structure-activity relationship (QSAR) modelling, network pharmacology, and bioactivity prediction using machine learning. Other emerging technologies such as genome editing and synthetic biology also provide additional opportunities to access and optimize valuable natural-product metabolites. Together, these tools can aid in identifying candidate molecules, elucidate potential mechanisms, and formulation development, although all of it requires experimental validation. Herbal medicines can modulate multiple molecular targets, hence can be advantageous for complex diseases. Analytical techniques such as hyphenated spectroscopy and metabolomics can further contribute to standardization and quality control. Nanocarrier systems and pharmacogenomic approaches can increase bioavailability and support more personalized therapeutic strategies. This review highlights integrated approaches for improving discovery, validation, and herbal therapeutic development. Conclusion: The combination of traditional knowledge with computational and analytical approaches provides a practical framework for herbal product-based drug discovery. Continued progress will depend on standardization, reproducible methodologies, and robust clinical evidence.
- Open Access
- 22 March 2026
- Published by Springer Nature in Beni-Suef University Journal of Basic and Applied Sciences
- Vol. 15 (1) , 29
Network pharmacology and computational dissection of Solanum trilobatum bioactives reveals modulation of steroid receptor associated signalling in breast cancer
Background: Breast cancer is the most common form of malignancy in women worldwide. Although chemotherapy has been improved, the major drawbacks demand alternative treatment plans. Bioactives based on plants have become a key focus of interest as complementary agents and Solanum trilobatum has been known to possess multiple pharmacological activities that include, antioxidant, antimicrobial, anti-inflammatory, and anti-cancer effects. The molecular paths of action of its anticancer effect, however, is mostly unexplored. Methods: An integrative in silico strategy combining network pharmacology, molecular docking, molecular dynamics (MD) simulations, and binding free energy calculations was employed to elucidate the anticancer mechanisms of S. trilobatum bioactives. Phytoconstituents were mined from curated databases and screened based on drug-likeness, ADMET properties, and predicted anti-neoplastic activity. Protein protein interaction networks, KEGG pathway enrichment, and Gene Ontology analyses were performed to identify key pathways and hub genes. Selected bioactives were docked against oncogenic targets using AutoDock Vina and Schrödinger Glide. The most promising protein ligand complexes were further validated through long-timescale MD simulations and MMPBSA binding free energy analysis. Results: The enrichment of the analysis by KEGG pathways demonstrated the PI3K-Akt signalling pathway as the pathway that was massively altered. Network analysis identified AKT1, TP53, TNF, STAT3, MYC, IL6, HIF1A, EGFR, CTNNB1, and CASP3 as hub genes. Molecular docking of rheochrysin, hypoxiside, cytochalasin and 4- p- coumatoylquinic acid to oncogenic proteins, HRAS, KRAS, NCOA3 (a nuclear coactivator of steroid receptors), PGR, and PIK3CB oncogenes was observed using AutoDock 4.2 and Schrodinger Glide with binding affinities displaying strong binding. Molecular dynamics simulations further confirmed stable and sustained interactions, particularly between KRAS–4-p-coumaroylquinic acid and TP53–Hypoxoside A complexes. Conclusion: These findings provide mechanistic insights into the anticancer potential of S. trilobatum , supporting its role as a promising source of bioactive compounds capable of modulating steroid receptor–associated signalling networks in breast cancer therapy. Graphic
- 22 March 2026
- Published by Springer Nature in Beni-Suef University Journal of Basic and Applied Sciences
- Vol. 15 (1) , 29
Open AccessNetwork pharmacology and computational dissection of Solanum trilobatum bioactives reveals modulation of steroid receptor associated signalling in breast cancer
Background: Breast cancer is the most common form of malignancy in women worldwide. Although chemotherapy has been improved, the major drawbacks demand alternative treatment plans. Bioactives based on plants have become a key focus of interest as complementary agents and Solanum trilobatum has been known to possess multiple pharmacological activities that include, antioxidant, antimicrobial, anti-inflammatory, and anti-cancer effects. The molecular paths of action of its anticancer effect, however, is mostly unexplored. Methods: An integrative in silico strategy combining network pharmacology, molecular docking, molecular dynamics (MD) simulations, and binding free energy calculations was employed to elucidate the anticancer mechanisms of S. trilobatum bioactives. Phytoconstituents were mined from curated databases and screened based on drug-likeness, ADMET properties, and predicted anti-neoplastic activity. Protein protein interaction networks, KEGG pathway enrichment, and Gene Ontology analyses were performed to identify key pathways and hub genes. Selected bioactives were docked against oncogenic targets using AutoDock Vina and Schrödinger Glide. The most promising protein ligand complexes were further validated through long-timescale MD simulations and MMPBSA binding free energy analysis. Results: The enrichment of the analysis by KEGG pathways demonstrated the PI3K-Akt signalling pathway as the pathway that was massively altered. Network analysis identified AKT1, TP53, TNF, STAT3, MYC, IL6, HIF1A, EGFR, CTNNB1, and CASP3 as hub genes. Molecular docking of rheochrysin, hypoxiside, cytochalasin and 4- p- coumatoylquinic acid to oncogenic proteins, HRAS, KRAS, NCOA3 (a nuclear coactivator of steroid receptors), PGR, and PIK3CB oncogenes was observed using AutoDock 4.2 and Schrodinger Glide with binding affinities displaying strong binding. Molecular dynamics simulations further confirmed stable and sustained interactions, particularly between KRAS–4-p-coumaroylquinic acid and TP53–Hypoxoside A complexes. Conclusion: These findings provide mechanistic insights into the anticancer potential of S. trilobatum , supporting its role as a promising source of bioactive compounds capable of modulating steroid receptor–associated signalling networks in breast cancer therapy. Graphic